The global opioid use disorder market revenue was around US$ 3.4 billion in 2023 and is estimated to reach US$ 9 billion by 2032, growing at a compound annual growth rate (CAGR) of 11.5% during the forecast period from 2024 to 2032.
Opioids are a set of painkillers that include drugs that lessen pain, relax muscles, and relieve stress. Medications including oxycodone, hydrocodone, fentanyl, codeine, morphine, methadone, and other pharmaceutical opioids are prescribed to relieve moderate to extreme pain. The relapsing brain and chronic illness referred to as opioid usage disorder (OUD) is characterized by extreme opioid seeking and usage despite side effects.
Market Driving Factors
Surging consideration of buprenorphine patches as an effective treatment is predicted to boost the market growth. This is because these patches are considered an effective therapy for Opioid Use Disorder treatment. Furthermore, several benefits associated with transdermal patches, such as facilitating the mode of drug delivery and decreasing pain, are traditional and self-administered. Furthermore, these transdermal patches can be a potential choice for patients needing around-the-clock opioid therapy for OUD.
Increasing engagement of governmental and non-governmental organizations to build awareness toward opioid overdose and its dangers is another crucial element boosting the market growth. This is because the number of opioid addicts has significantly surged and this has prompted various organizations to take a vast approach toward addressing the issue. As a result, various countries have stepped up their efforts to help patients and reduce the impact of opioid dependence.
Side effects associated with opioid utilization disorder drugs are predicted to restrict the market growth.
Regional Analysis
North America dominated the market in terms of revenue and is estimated to continue its dominance during the projection period. This can be generally attributed to various factors such as a surge in the number of product approvals and launches for opioid use disorder, and the raised in the prevalence of chronic illnesses such as cardiac, cancer diseases, and orthopedic diseases in the region.
Asia-Pacific is expected to dominate the market in terms of the largest shares. This is mainly due to several factors such as a surge in the number of geriatric populations, an increase in the awareness regarding availability of healthcare services, and a rise in the number of chronic disorders. For instance, according to UNFPA, the number of geriatric people in this region will triple reaching 1.3 billion by 2050.
Segmentation Insights
Drug Type Insight
The agonist segment dominates the market in terms of shares. This is primarily owing to the increase in the prevalence of chronic pain, the high prevalence of opioid abuse, and the surging geriatric population prone to painful illness.
The antagonist segment is estimated to dominate the market in terms of growth rate. This is mainly due to the surge in research & development expenses by key players, strategic partnerships among key companies, and continuous research on naltrexone drugs.
Age Group Insight
The 19 to 39 segments dominated the market in terms of the rate. This can be majorly attributed to the surge in the prevalence of chronic illnesses such as cardiovascular, orthopedic, and cancer diseases associated with chronic pain.
Route of Administration Insight
The intravenous segment dominates the market in terms of shares. This is due to the growth in the demand for intravenous routes for opioid use illness treatment.
Distribution Channel Insight
The hospital pharmacy segment dominated the market in terms of revenue and is predicted to maintain its dominance. This can be majorly attributed to the increase in the number of hospital pharmacies, the surge in expense by the government to grow healthcare infrastructure, and the rise in the prevalence of opioid use disorder.
Prominent Companies
Segmentation Outline
The global opioid use disorder market segmentation focuses on the Drug Type, Age Group, Route of Administration, Distribution Channel, and Region.
By Drug Type
By Age Group
By Route of Administration
By Distribution Channel
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL OPIOID USE DISORDER MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: OPIOID USE DISORDER MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL OPIOID USE DISORDER MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL OPIOID USE DISORDER MARKET, BY DRUG TYPE
5.1 OVERVIEW
5.2 AGONIST
5.2.1 METHADONE
5.2.2 BUPRENORPHINE
5.3 ANTAGONIST
6 GLOBAL OPIOID USE DISORDER MARKET, BY AGE GROUP
6.1 OVERVIEW
6.2 19 TO 39
6.3 40 TO 59
6.4 AGED 60 AND OVER
7 GLOBAL OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION
7.1 OVERVIEW
7.2 ORAL
7.3 INTRAVENOUS
7.4 SUBLINGUAL
8 GLOBAL OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL
8.1 OVERVIEW
8.2 HOSPITAL PHARMACY
8.3 RETAIL PHARMACY
9 GLOBAL OPIOID USE DISORDER MARKET, BY GEOGRAPHY
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO
9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3.1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA
9.6 SOUTH AMERICA
9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA
10 GLOBAL OPIOID USE DISORDER MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES
10.4 COMPETITIVE DASHBOARD
10.5 PRODUCT MAPPING
10.6 TOP PLAYER POSITIONING, 2022
10.7 COMPETITIVE HEATMAP
10.8 TOP WINNING STRATEGIES
11 COMPANY PROFILES
11.1 HIKMA PHARMACEUTICALS PLC
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS
11.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.2 ALKERMES INC.
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS
11.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.3 MALLINCKRODT PHARMACEUTICALS
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.4 ASTRAZENECA PLC
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.5 NYC HEALTH HOSPITALS
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.6 OREXO AB
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.7 CAMURUS
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.8 BRAEBURN PHARMACEUTICALS
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.9 TITAN PHARMACEUTICALS INC.
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.10 VIATRIS INC
11.10.1 OVERVIEW
11.10.2 FINANCIAL PERFORMANCE
11.10.3 PRODUCT OUTLOOK
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.11 BIODELIVERY SCIENCES INTERNATIONAL INC.
11.11.1 OVERVIEW
11.11.2 FINANCIAL PERFORMANCE
11.11.3 PRODUCT OUTLOOK
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.12 RECKITT BENCKISER PHARMACEUTICALS INC
11.12.1 OVERVIEW
11.12.2 FINANCIAL PERFORMANCE
11.12.3 PRODUCT OUTLOOK
11.12.4 KEY DEVELOPMENTS
11.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.13 DR REDDY LABORATORIES LTD
11.13.1 OVERVIEW
11.13.2 FINANCIAL PERFORMANCE
11.13.3 PRODUCT OUTLOOK
11.13.4 KEY DEVELOPMENTS
11.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.14 PEAR THERAPEUTICS
11.14.1 OVERVIEW
11.14.2 FINANCIAL PERFORMANCE
11.14.3 PRODUCT OUTLOOK
11.14.4 KEY DEVELOPMENTS
11.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.15 SANDOZ
11.15.1 OVERVIEW
11.15.2 FINANCIAL PERFORMANCE
11.15.3 PRODUCT OUTLOOK
11.15.4 KEY DEVELOPMENTS
11.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.16 INDIVIOR PLC
11.16.1 OVERVIEW
11.16.2 FINANCIAL PERFORMANCE
11.16.3 PRODUCT OUTLOOK
11.16.4 KEY DEVELOPMENTS
11.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved